Bioprocessing - Upstream & Downstream

Understanding AAV production and characterization processes – and establishing strategies for success.

How increased biological understanding and advanced technology are generating new antibody-based modalities with exciting potential.

How fucosylation-deficient CHO cell hosts can help enhance the potency of monoclonal antibody-based biotherapeutics

The wait is over. Our annual celebration of the pharma industry’s most influential individuals has returned!

From resins to buffers to single-use technologies – there are many opportunities to improve downstream processes.

How the thoughtful adoption of new technology can both problem-solve and future- proof critical processes in biomanufacturing

A video interview discussing the challenges of viral vectors

Download our eBook to find out how the industry is trying to be more sustainable.

Why 2023 is the year that antibody manufacturers should embrace CRISPR gene editing.

Great successes are being seen in gene therapy, but there are still gaps in our scientific knowledge – and our manufacturing prowess.